Roswell Park Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Roswell Park Cancer Institute sits in the top decile of US sponsors by registered trial count (#98 of 15,742 sponsors by registered trial count).
Roswell Park Cancer Institute: 365 sponsored US clinical trials, 57 recruiting.
Roswell Park Cancer Institute sponsors 365 registered US clinical trials on ClinicalTrials.gov, 57 of them currently recruiting, and 200 completed. 7 of these trials are in Phase 3-4 (later-stage) and 238 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Leukemia, with 9 trials.
Top-decile sponsor footprint
Roswell Park Cancer Institute ranks in the top decile of sponsors by registered trial count (#98 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
200 of 279 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
365 total, page 4 of 8
Art in Improving Outcomes in Participants Undergo Surgery
NCT03688945
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
NCT02953457
Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT02947386
Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03685695
Talking Pictures Social Media Intervention in Reducing Depressive Symptoms and Improving Spiritual Well-Being and Quality of Life in Adolescent and Young Adult Cancer Patients
NCT03679585
Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer
NCT02965976
Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy
NCT02857374
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02853318
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
NCT02713373
Informational Intervention in Increasing Lactation Practices by African American Women
NCT03680235
Omission of Intact Parathyroid Hormone Testing During Surgery in Treating Patients With Primary Hyperparathyroidism
NCT03011736
Nicotine Delivery From Novel Non-Tobacco Electronic System in Smokers
NCT02575885
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
NCT02452463
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT02399215
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
NCT02393755
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT02414724
Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation
NCT02531906
Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer
NCT02227940
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT02159950
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation in Treating Radiation-Induced Xerostomia in Patients With Head and Neck Cancer
NCT02474095
Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
NCT02170389
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
NCT02166905
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02029417
Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease
NCT02877641
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
NCT02068157
Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery
NCT01854684
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
NCT01948141
Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT02072486
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
NCT01896778
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
NCT01886235
Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
NCT01876446
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT01834248
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery
NCT01892930
Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
NCT01835223
Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T
NCT01833208
Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01753908
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
NCT01754519
Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma
NCT01744171
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
NCT01781741
Biomarkers in Post-Menopausal Women Receiving Flaxseed
NCT01698294
Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers
NCT01771627
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
NCT01545141
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
NCT01250470
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT01536054
PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic
NCT01540253
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT01550185
Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
NCT01573780
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
NCT01536067
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
NCT01497392
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
NCT01522820
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 123 |
| Phase 2 | 115 |
| Phase 3 | 5 |
| Phase 4 | 2 |
What is open in the Roswell Park Cancer Institute pipeline
57 recruiting of 365 indexed (16% open); 200 completed (55%).
Phase mix: 7 late (III/IV) vs 238 early (I/II) (early-phase heavy).
Top condition: Leukemia (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Roswell Park Cancer Institute: open-pipeline peers nationwide
Peers matched on 365 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
Roswell Park Cancer Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 365 trials (± recruiting share)
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- New York State Psychiatric Institute · 364 trials · 3% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 16% open enrollment (± trial volume)
- Cambridge Health Alliance · 16% recruiting · 45 trials
- Louisiana State University Health Sciences Center in New Orleans · 16% recruiting · 45 trials
- University of Southern California · 16% recruiting · 617 trials
- Incyte Corporation · 15% recruiting · 239 trials
Related
What to do with this Roswell Park Cancer Institute page
365 registered trials is a research-attention snapshot, not an endorsement of Roswell Park Cancer Institute or any single study.
- 57 of Roswell Park Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Leukemia is the condition Roswell Park Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Roswell Park Cancer Institute pipeline card: 365 registered trials from official public datasets.Report a data error.